NEOsphere Biotechnologies offers its strategic partners a unique proteomics-based platform to significantly advance their TPD drug discovery programs and create broad pipelines of novel, high-value targets. Combining best-in-class high-throughput data-independent mass spectrometry (DIA-PASEF) with expert data analysis, NEOsphere Biotechnologies performs unbiased screening of entire degrader libraries against more than 10,000 proteins with unprecedented sensitivity, precision, and data completeness.
Our platform is suitable to characterize all types of degraders (e.g., PROTACs, molecular glues, monovalent degraders, DUB inhibitors), identify novel targets, monitor proteome-wide selectivity, and detect molecules that potentially act through new E3 ligases and emerging TPD mechanisms.
Additionally, mechanistic validation of neosubstrates, degrader-induced E3 ligase binding or degrader-induced modification is performed using interactomics and ubiquitination analysis at an unparalleled depth of 50,000 sites.
